{"nctId":"NCT01444781","briefTitle":"Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants","startDateStruct":{"date":"2011-09"},"conditions":["Diphtheria","Tetanus","Whooping Cough","Hepatitis B","Poliomyelitis"],"count":1106,"armGroups":[{"label":"Study Group 1","type":"EXPERIMENTAL","interventionNames":["Biological: DTaP-IPV-Hep B-PRP~T combined vaccine + Pneumococcal polysaccharide"]},{"label":"Study Group 2","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: DTaP-Hep B-IPV // Hib Vaccine + Pneumococcal polysaccharide"]},{"label":"Study Group 3","type":"EXPERIMENTAL","interventionNames":["Biological: DTaP-IPV-Hep B-PRP~T + Pneumococcal polysaccharide vaccine"]}],"interventions":[{"name":"DTaP-IPV-Hep B-PRP~T combined vaccine + Pneumococcal polysaccharide","otherNames":["DTaP-IPV-Hep B-PRP~T vaccine","Prevenar™"]},{"name":"DTaP-Hep B-IPV // Hib Vaccine + Pneumococcal polysaccharide","otherNames":["Infanrix hexa™","Prevenar™"]},{"name":"DTaP-IPV-Hep B-PRP~T + Pneumococcal polysaccharide vaccine","otherNames":["DTaP-IPV-Hep B-PRP~T combined vaccine","Prevenar™"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Aged 12 to 24 months on the day of inclusion.\n* Informed consent form has been signed and dated by the parent(s) or other legally acceptable representative (and by an independent witness(es) if required by local regulations).\n* Subject and parent/guardian are able to attend all scheduled visits and to comply with all trial procedures.\n* Toddlers previously included in Study A3L24 who completed the three-dose primary series vaccination of either DTaP-IPV-Hep B-PRP\\~T or Infanrix hexa™ at 2,4 and 6 months of age according to protocol (both concomitantly administered with Prevenar™ and Rotarix™).\n\nExclusion Criteria:\n\n* Participation in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the booster vaccinations.\n* Planned participation in another clinical trial during the present trial period.\n* Receipt of any vaccine in the 4 weeks preceding the booster vaccinations, except in case of pandemic influenza vaccination, which may be received at least two weeks before the study vaccines.\n* Planned receipt of any vaccine in the 4 weeks following the trial vaccinations.\n* Previous booster vaccination against pertussis, tetanus, diphtheria, poliomyelitis, Haemophilus influenzae type b, hepatitis B and pneumococcal infection(s) with either the trial vaccine or another vaccine.\n* Receipt of blood or blood-derived products in the past 3 months, which might interfere with assessment of the immune response.\n* Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 3 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).\n* Laboratory-confirmed or clinical suspicion of personal or maternal seropositivity for Human Immunodeficiency Virus (HIV), hepatitis B, or hepatitis C, as reported by the parent/guardian.\n* History of pertussis, tetanus, diphtheria, poliomyelitis, Haemophilus influenzae type b, hepatitis B and pneumococcal infection(s), confirmed either clinically, serologically, or microbiologically.\n* At high risk for opportunistic infection during the trial.\n* Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine(s) used in the trial or to a vaccine containing any of the same substances.\n* History of contraindication to receipt of pertussis-containing vaccine.\n* Laboratory-confirmed or clinical suspicion of thrombocytopenia contraindicating Intramuscular vaccination.\n* Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination.\n* History of seizures .\n* Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion.\n* Receipt of oral or injected antibiotic therapy within 72 hours prior to the first blood draw\n* Febrile illness (temperature ≥ 38.0°C) or moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination.","healthyVolunteers":true,"sex":"ALL","minimumAge":"12 Months","maximumAge":"24 Months","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Summary of Diphtheria and Tetanus Post Primary Series Antibodies, Persistence and Booster Response Following Vaccination With Either DTaP-IPV Hep B-PRP T Vaccine or Infanrix Hexa Vaccine","description":"Anti-Diphtheria (D) antibodies were measured by a toxin neutralization test. Anti-Tetanus (T) antibodies were measured by enzyme-linked immunosorbent assay (ELISA). Antibody persistence for anti-Diphtheria and anti-Tetanus antibodies was defined as titers ≥0.01 IU/mL and ≥0.1 IU/mL before the booster dose at Day 0. Booster response to Diphtheria and Tetanus was defined as antibody titers ≥0.01 IU/mL and ≥0.1 IU/mL at Day 30 post-booster vaccination.\n\nDay 140 = Primary series; Day 0 = Pre-booster; and Day 30 = Post-booster titers","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"392","spread":null},{"groupId":"OG001","value":"391","spread":null},{"groupId":"OG002","value":"259","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"308","spread":null},{"groupId":"OG001","value":"290","spread":null},{"groupId":"OG002","value":"197","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"382","spread":null},{"groupId":"OG001","value":"378","spread":null},{"groupId":"OG002","value":"246","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"156","spread":null},{"groupId":"OG001","value":"153","spread":null},{"groupId":"OG002","value":"70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"393","spread":null},{"groupId":"OG001","value":"387","spread":null},{"groupId":"OG002","value":"254","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"393","spread":null},{"groupId":"OG001","value":"386","spread":null},{"groupId":"OG002","value":"254","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"392","spread":null},{"groupId":"OG001","value":"391","spread":null},{"groupId":"OG002","value":"258","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"392","spread":null},{"groupId":"OG001","value":"390","spread":null},{"groupId":"OG002","value":"258","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"389","spread":null},{"groupId":"OG001","value":"386","spread":null},{"groupId":"OG002","value":"255","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"289","spread":null},{"groupId":"OG001","value":"286","spread":null},{"groupId":"OG002","value":"196","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"392","spread":null},{"groupId":"OG001","value":"385","spread":null},{"groupId":"OG002","value":"254","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"391","spread":null},{"groupId":"OG001","value":"385","spread":null},{"groupId":"OG002","value":"254","spread":null}]}]}]},{"type":"PRIMARY","title":"Summary of Pertussis and Filamentous Haemagglutinin Post Primary Series Antibodies, Persistence and Booster Response Following Vaccination With Either DTaP-IPV-Hep B-PRP~T Vaccine or Infanrix Hexa Vaccine","description":"Anti-Pertussis toxin (PT) and anti-Filamentous haemagglutinin (FHA) antibodies were measured by ELISA. Antibody persistence for anti-PT and anti-FHA was defined as titers ≥ lower limit of quantitation (LLOQ) before the booster dose at Day 0. Booster responses for PT and FHA at Day 30 were defined as: pre-vaccination antibody concentrations \\< LLOQ and post-vaccination levels ≥ 4 x LLOQ, pre-vaccination antibody concentrations ≥ LLOQ but \\< 4 x LLOQ and post/pre vaccination ≥ 4, and pre-vaccination antibody concentrations ≥ 4 x LLOQ and post/pre-vaccination ≥ 2.\n\nDay 140 = Primary series; Day 0 = Pre-booster; and Day 30 = Post-booster titers.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"393","spread":null},{"groupId":"OG001","value":"391","spread":null},{"groupId":"OG002","value":"259","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"344","spread":null},{"groupId":"OG001","value":"349","spread":null},{"groupId":"OG002","value":"225","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"391","spread":null},{"groupId":"OG001","value":"383","spread":null},{"groupId":"OG002","value":"254","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"353","spread":null},{"groupId":"OG001","value":"351","spread":null},{"groupId":"OG002","value":"234","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"375","spread":null},{"groupId":"OG001","value":"365","spread":null},{"groupId":"OG002","value":"245","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"391","spread":null},{"groupId":"OG001","value":"390","spread":null},{"groupId":"OG002","value":"259","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"389","spread":null},{"groupId":"OG001","value":"384","spread":null},{"groupId":"OG002","value":"253","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"390","spread":null},{"groupId":"OG001","value":"385","spread":null},{"groupId":"OG002","value":"254","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"336","spread":null},{"groupId":"OG001","value":"334","spread":null},{"groupId":"OG002","value":"235","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"370","spread":null},{"groupId":"OG001","value":"367","spread":null},{"groupId":"OG002","value":"249","spread":null}]}]}]},{"type":"PRIMARY","title":"Summary of Polio Antibodies Post Primary Series, Persistence and Booster Response Following Vaccination With Either DTaP-IPV-Hep B-PRP~T Vaccine or Infanrix Hexa Vaccine","description":"Anti-Poliovirus types 1, 2, and 3 antibodies were measured by neutralization assay. Antibody persistence for anti-Poliovirus 1, 2, and 3 was defined as antibody titers ≥8 (1/dil) before the booster dose at Day 0. Booster response to Poliovirus 1, 2, and 3 was defined as antibody titers ≥8 (1/dil) at Day 30.\n\nDay 140 = Primary series; Day 0 = Pre-booster; and Day 30 = Post-booster titers.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"338","spread":null},{"groupId":"OG001","value":"329","spread":null},{"groupId":"OG002","value":"214","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"334","spread":null},{"groupId":"OG001","value":"320","spread":null},{"groupId":"OG002","value":"210","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"339","spread":null},{"groupId":"OG001","value":"327","spread":null},{"groupId":"OG002","value":"212","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"338","spread":null},{"groupId":"OG001","value":"327","spread":null},{"groupId":"OG002","value":"214","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"335","spread":null},{"groupId":"OG001","value":"328","spread":null},{"groupId":"OG002","value":"213","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"340","spread":null},{"groupId":"OG001","value":"327","spread":null},{"groupId":"OG002","value":"212","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"338","spread":null},{"groupId":"OG001","value":"328","spread":null},{"groupId":"OG002","value":"214","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"324","spread":null},{"groupId":"OG001","value":"309","spread":null},{"groupId":"OG002","value":"211","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"340","spread":null},{"groupId":"OG001","value":"326","spread":null},{"groupId":"OG002","value":"212","spread":null}]}]}]},{"type":"PRIMARY","title":"Summary of Hepatitis B and Haemophilus Influenzae Type B Post Primary Series Antibodies; Antibody Persistence, and Booster Response Following Vaccination With Either DTaP-IPV-Hep B-PRP~T Vaccine or Infanrix Hexa Vaccine","description":"Anti-Hepatitis B antibodies were measured by the commercially available VITROS ECi/ECiQ Immunodiagnostic System. Anti-Haemophilus influenza type b capsular polyribosyl ribitol phosphate (PRP) antibodies were measured using a Farr type radioimmunoassay that used radiolabeled PRP (3H PRP) in the presence of 36Cl (volume marker). Anti-Hepatitis antibody titers ≥ 10 mIU/mL and ≥ 100 mIU/mL at Day 0 confirmed antibody persistence and booster response at Day 30. Anti-PRP antibody titers ≥ 0.15 µg/ml and ≥ 1.0 µg/ml at Day 0 confirmed antibody persistence and booster response at Day 30.\n\nDay 140 = Primary series; Day 0 = Pre-booster; and Day 30 = Post-booster titers.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"391","spread":null},{"groupId":"OG001","value":"391","spread":null},{"groupId":"OG002","value":"260","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"389","spread":null},{"groupId":"OG001","value":"387","spread":null},{"groupId":"OG002","value":"259","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"386","spread":null},{"groupId":"OG001","value":"382","spread":null},{"groupId":"OG002","value":"257","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"327","spread":null},{"groupId":"OG001","value":"333","spread":null},{"groupId":"OG002","value":"213","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"394","spread":null},{"groupId":"OG001","value":"391","spread":null},{"groupId":"OG002","value":"259","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"386","spread":null},{"groupId":"OG001","value":"384","spread":null},{"groupId":"OG002","value":"257","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"370","spread":null},{"groupId":"OG001","value":"375","spread":null},{"groupId":"OG002","value":"246","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"297","spread":null},{"groupId":"OG001","value":"305","spread":null},{"groupId":"OG002","value":"188","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"290","spread":null},{"groupId":"OG001","value":"304","spread":null},{"groupId":"OG002","value":"197","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"110","spread":null},{"groupId":"OG001","value":"129","spread":null},{"groupId":"OG002","value":"73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"395","spread":null},{"groupId":"OG001","value":"391","spread":null},{"groupId":"OG002","value":"258","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"391","spread":null},{"groupId":"OG001","value":"387","spread":null},{"groupId":"OG002","value":"258","spread":null}]}]}]},{"type":"SECONDARY","title":"Summary of Geometric Mean Titers to Vaccine Antibodies Post Primary Vaccination Series; Before and After Booster Vaccination With Either DTaP-IPV-Hep B-PRP~T Vaccine or Infanrix Hexa Vaccine.","description":"Anti-Diphtheria antibodies were measured by a toxin neutralization test. Anti-Tetanus, anti-PT, and anti-FHA antibodies were measured by ELISA. Anti-Poliovirus types 1, 2, and 3 were measured by neutralization assay. Anti-Hepatitis B antibodies were measured by the commercially available VITROS ECi/ECiQ Immunodiagnostic System. Anti-PRP antibodies were measured using a Farr type radioimmunoassay that used radiolabeled PRP (3H PRP) in the presence of 36Cl (volume marker).\n\nDay 140 = Primary series; Day 0 = Pre-booster; and Day 30 = Post-booster titers.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.265","spread":null},{"groupId":"OG001","value":"0.254","spread":null},{"groupId":"OG002","value":"0.251","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.077","spread":null},{"groupId":"OG001","value":"0.074","spread":null},{"groupId":"OG002","value":"0.059","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.55","spread":null},{"groupId":"OG001","value":"4.40","spread":null},{"groupId":"OG002","value":"6.05","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.50","spread":null},{"groupId":"OG001","value":"1.54","spread":null},{"groupId":"OG002","value":"1.80","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.208","spread":null},{"groupId":"OG001","value":"0.224","spread":null},{"groupId":"OG002","value":"0.201","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.72","spread":null},{"groupId":"OG001","value":"5.21","spread":null},{"groupId":"OG002","value":"7.52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","spread":null},{"groupId":"OG001","value":"102","spread":null},{"groupId":"OG002","value":"97.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.43","spread":null},{"groupId":"OG001","value":"8.47","spread":null},{"groupId":"OG002","value":"7.41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"154","spread":null},{"groupId":"OG001","value":"191","spread":null},{"groupId":"OG002","value":"140","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"179","spread":null},{"groupId":"OG001","value":"187","spread":null},{"groupId":"OG002","value":"120","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.2","spread":null},{"groupId":"OG001","value":"23.4","spread":null},{"groupId":"OG002","value":"14.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"316","spread":null},{"groupId":"OG001","value":"418","spread":null},{"groupId":"OG002","value":"260","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"656","spread":null},{"groupId":"OG001","value":"705","spread":null},{"groupId":"OG002","value":"1276","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"132","spread":null},{"groupId":"OG001","value":"134","spread":null},{"groupId":"OG002","value":"224","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2140","spread":null},{"groupId":"OG001","value":"2633","spread":null},{"groupId":"OG002","value":"2978","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1152","spread":null},{"groupId":"OG001","value":"1241","spread":null},{"groupId":"OG002","value":"1945","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"251","spread":null},{"groupId":"OG001","value":"289","spread":null},{"groupId":"OG002","value":"380","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4232","spread":null},{"groupId":"OG001","value":"4887","spread":null},{"groupId":"OG002","value":"6369","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1169","spread":null},{"groupId":"OG001","value":"1108","spread":null},{"groupId":"OG002","value":"1948","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"128","spread":null},{"groupId":"OG001","value":"126","spread":null},{"groupId":"OG002","value":"207","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3569","spread":null},{"groupId":"OG001","value":"3322","spread":null},{"groupId":"OG002","value":"6015","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3050","spread":null},{"groupId":"OG001","value":"3180","spread":null},{"groupId":"OG002","value":"2910","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"386","spread":null},{"groupId":"OG001","value":"406","spread":null},{"groupId":"OG002","value":"336","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8462","spread":null},{"groupId":"OG001","value":"11218","spread":null},{"groupId":"OG002","value":"9688","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.19","spread":null},{"groupId":"OG001","value":"3.60","spread":null},{"groupId":"OG002","value":"2.13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.482","spread":null},{"groupId":"OG001","value":"0.556","spread":null},{"groupId":"OG002","value":"0.455","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.4","spread":null},{"groupId":"OG001","value":"41.5","spread":null},{"groupId":"OG002","value":"56.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Summary of Immune Response Against Serotypes in the Prevenar Vaccine After Booster Vaccination With Either DTaP-IPV-Hep B-PRP~T Vaccine or Infanrix Hexa Vaccine","description":"Anti-Streptococcus pneumococcal type specific antibody (anti-Pn PS) was measured by ELISA. Booster response to pneumococcal serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F was defined as antibody titers ≥0.35 µg/mL at Day 30.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"160","spread":null},{"groupId":"OG001","value":"146","spread":null},{"groupId":"OG002","value":"94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"155","spread":null},{"groupId":"OG001","value":"145","spread":null},{"groupId":"OG002","value":"93","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"161","spread":null},{"groupId":"OG001","value":"147","spread":null},{"groupId":"OG002","value":"94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"161","spread":null},{"groupId":"OG001","value":"147","spread":null},{"groupId":"OG002","value":"94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"160","spread":null},{"groupId":"OG001","value":"147","spread":null},{"groupId":"OG002","value":"94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"161","spread":null},{"groupId":"OG001","value":"144","spread":null},{"groupId":"OG002","value":"94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"158","spread":null},{"groupId":"OG001","value":"144","spread":null},{"groupId":"OG002","value":"93","spread":null}]}]}]},{"type":"SECONDARY","title":"Summary of Geometric Mean Titers to Prevenar Vaccine Antibodies After Booster Vaccination With Either DTaP-IPV-Hep B-PRP~T Vaccine or Infanrix Hexa Vaccine","description":"Anti-Streptococcus pneumococcal type specific antibody (anti-Pn PS) was measured by ELISA.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.79","spread":null},{"groupId":"OG001","value":"3.03","spread":null},{"groupId":"OG002","value":"3.58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.87","spread":null},{"groupId":"OG001","value":"8.98","spread":null},{"groupId":"OG002","value":"9.34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.51","spread":null},{"groupId":"OG001","value":"2.86","spread":null},{"groupId":"OG002","value":"2.92","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.6","spread":null},{"groupId":"OG001","value":"13.2","spread":null},{"groupId":"OG002","value":"12.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.37","spread":null},{"groupId":"OG001","value":"2.63","spread":null},{"groupId":"OG002","value":"3.40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.01","spread":null},{"groupId":"OG001","value":"3.74","spread":null},{"groupId":"OG002","value":"3.72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.98","spread":null},{"groupId":"OG001","value":"7.20","spread":null},{"groupId":"OG002","value":"9.30","spread":null}]}]}]},{"type":"SECONDARY","title":"Summary of Booster Response to Vaccine Antigens Before and After Booster Vaccination With Either DTaP-IPV-Hep B-PRP~T Vaccine or Infanrix Hexa Vaccine By Age Strata","description":"Anti-PT and anti-FHA antibodies were measured by ELISA.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"104","spread":null},{"groupId":"OG002","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null},{"groupId":"OG001","value":"92","spread":null},{"groupId":"OG002","value":"53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"99","spread":null},{"groupId":"OG002","value":"56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"133","spread":null},{"groupId":"OG001","value":"118","spread":null},{"groupId":"OG002","value":"86","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"132","spread":null},{"groupId":"OG001","value":"121","spread":null},{"groupId":"OG002","value":"89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"138","spread":null},{"groupId":"OG001","value":"125","spread":null},{"groupId":"OG002","value":"94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"111","spread":null},{"groupId":"OG001","value":"127","spread":null},{"groupId":"OG002","value":"78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"134","spread":null},{"groupId":"OG001","value":"138","spread":null},{"groupId":"OG002","value":"92","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"136","spread":null},{"groupId":"OG001","value":"141","spread":null},{"groupId":"OG002","value":"95","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"103","spread":null},{"groupId":"OG001","value":"105","spread":null},{"groupId":"OG002","value":"59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76","spread":null},{"groupId":"OG001","value":"78","spread":null},{"groupId":"OG002","value":"53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96","spread":null},{"groupId":"OG001","value":"99","spread":null},{"groupId":"OG002","value":"58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"143","spread":null},{"groupId":"OG001","value":"130","spread":null},{"groupId":"OG002","value":"95","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"127","spread":null},{"groupId":"OG001","value":"118","spread":null},{"groupId":"OG002","value":"88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"136","spread":null},{"groupId":"OG001","value":"124","spread":null},{"groupId":"OG002","value":"94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"143","spread":null},{"groupId":"OG001","value":"149","spread":null},{"groupId":"OG002","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"133","spread":null},{"groupId":"OG001","value":"138","spread":null},{"groupId":"OG002","value":"94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"138","spread":null},{"groupId":"OG001","value":"144","spread":null},{"groupId":"OG002","value":"97","spread":null}]}]}]},{"type":"SECONDARY","title":"Summary of Geometric Mean Titers to Vaccine Antigens After Booster Vaccination With Either DTaP-IPV-Hep B-PRP~T Vaccine or Infanrix Hexa Vaccine by Age Strata","description":"Anti-Diphtheria antibodies were measured by a toxin neutralization test. Anti-FHA antibodies were measured by ELISA. Anti-Poliovirus types 1, 2, and 3 were measured by neutralization assay.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.20","spread":null},{"groupId":"OG001","value":"2.73","spread":null},{"groupId":"OG002","value":"3.82","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.39","spread":null},{"groupId":"OG001","value":"4.77","spread":null},{"groupId":"OG002","value":"6.56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.14","spread":null},{"groupId":"OG001","value":"5.77","spread":null},{"groupId":"OG002","value":"7.34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"235","spread":null},{"groupId":"OG001","value":"268","spread":null},{"groupId":"OG002","value":"197","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"339","spread":null},{"groupId":"OG001","value":"453","spread":null},{"groupId":"OG002","value":"280","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"365","spread":null},{"groupId":"OG001","value":"533","spread":null},{"groupId":"OG002","value":"287","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2509","spread":null},{"groupId":"OG001","value":"2616","spread":null},{"groupId":"OG002","value":"5617","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3944","spread":null},{"groupId":"OG001","value":"3261","spread":null},{"groupId":"OG002","value":"5409","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4119","spread":null},{"groupId":"OG001","value":"4061","spread":null},{"groupId":"OG002","value":"6889","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Reporting a Solicited Injection Site or Systemic Reactions Following Booster Vaccination With Either DTaP-IPV-Hep B-PRP~T Vaccine or Infanrix Hexa Vaccine","description":"Solicited injection site: Pain, Erythema, Swelling, and Extensive swelling of vaccinated limb; Solicited systemic reactions: Pyrexia (Temperature), Vomiting, Crying, Somnolence, Anorexia, and Irritability. Grade 3 Injection site: Pain, Cries if limb is moved or reduced movement; Erythema and Swelling, ≥5 cm; Extensive swelling of limb, Severe. Grade 3 Systemic reactions: Pyrexia (Temperature) \\>39.5˚C; Vomiting, ≥ 6 times per 24 hours or needing parenteral nutrition; Crying, \\>3 hours; Somnolence, Sleeping often or difficulty waking; Anorexia, refuses ≥3 meals; and Irritability, Inconsolable.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"232","spread":null},{"groupId":"OG001","value":"205","spread":null},{"groupId":"OG002","value":"160","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"112","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"86","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null},{"groupId":"OG001","value":"56","spread":null},{"groupId":"OG002","value":"49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"114","spread":null},{"groupId":"OG001","value":"99","spread":null},{"groupId":"OG002","value":"91","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"39","spread":null},{"groupId":"OG002","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"148","spread":null},{"groupId":"OG001","value":"139","spread":null},{"groupId":"OG002","value":"102","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"124","spread":null},{"groupId":"OG001","value":"113","spread":null},{"groupId":"OG002","value":"85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"118","spread":null},{"groupId":"OG001","value":"121","spread":null},{"groupId":"OG002","value":"90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"201","spread":null},{"groupId":"OG001","value":"176","spread":null},{"groupId":"OG002","value":"146","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Reporting a Solicited Injection Site Following Booster Vaccination With Prevenar Vaccine","description":"Solicited injection site: Pain, Erythema, Swelling, and Extensive swelling of vaccinated limb. Grade 3 Injection site: Pain, cries if limb is moved or reduced movement; Erythema and Swelling, ≥5 cm; and Extensive swelling of limb, Severe.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"224","spread":null},{"groupId":"OG001","value":"184","spread":null},{"groupId":"OG002","value":"140","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"77","spread":null},{"groupId":"OG002","value":"52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"42","spread":null},{"groupId":"OG002","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":13,"n":416},"commonTop":["Injection site Pain","Irritability","Crying","Anorexia","Drowsiness"]}}}